Gut microbiota and host metabolism in liver cirrhosis

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11597-11608

  Usami, Makoto ^a,b   Miyoshi, Makoto ^a   Yamashita, Hayato ^a  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Fatty acids; Liver cirrhosis; Metabolism; Microbiota; Probiotics

Indexed keywords

AMINO ACID; ARACHIDONIC ACID; CYTOKINE; DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; SYNBIOTIC AGENT; VITAMIN;

ALCOHOL LIVER DISEASE; ARTICLE; BACTEREMIA; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; CHRONIC DISEASE; DYSBIOSIS; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FECES MICROFLORA; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PROTECTION; METABOLIC LIVER DISEASE; METABOLISM; NONALCOHOLIC FATTY LIVER; NUTRITION; OBESITY; PHOSPHOLIPID BLOOD LEVEL; PROGNOSIS; ANIMAL; BACTERIUM; ENERGY METABOLISM; HOST PATHOGEN INTERACTION; INTESTINE; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; BACTERIA; BACTERIAL TRANSLOCATION; DYSBIOSIS; ENERGY METABOLISM; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; LIVER CIRRHOSIS; PROBIOTICS;

EID: 84947274561     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11597     Document Type: Article

References (108)

1. Hamer HM, De Preter V, Windey K, Verbeke K. Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol 2 012; 302: G1-G9 [PMID: 22016433 DOI: 10.1152/ajpgi.00048.2011]
2. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol 2015; 21: 1691-1702 [PMID: 25684933 DOI: 10.3748/wjg.v21.i6.1691]
3. Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe 2012; 12: 496-508 [PMID: 23084918 DOI: 10.1016/j.chom.2012.09.009]
4. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45: 744-757 [PMID: 16979776]
5. Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol 2012; 18: 6693-6700 [PMID: 23239905 DOI: 10.3748/wjg.v18.i46.6693]
6. Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol 2015; 7: 425-442 [PMID: 25848468 DOI: 10.4254/wjh.v7.i3.425]
7. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006; 130: S78-S90 [PMID: 16473077]
8. Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 2013; 58: 1020-1027 [PMID: 23183530 DOI: 10.1016/j.jhep.2012.11.023]
9. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015; 148: 30-36 [PMID: 25447847 DOI: 10.1053/j.gastro.2014.10.042]
10. Visschers RG, Luyer MD, Schaap FG, Olde Damink SW, Soeters PB. The gut-liver axis. Curr Opin Clin Nutr Metab Care 2013; 16: 576-581 [PMID: 23873346 DOI: 10.1097/MCO.0b013e32836410a4]
11. Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobi li V, Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci 2014; 15: 684-711 [PMID: 24402126 DOI: 10.3390/ijms15010684]
12. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267 [PMID: 22674330 DOI: 10.1126/science.1223 813]
13. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol 2014; 28: 1221-1238 [PMID: 24892638 DOI: 10.1210/me.2014-1108]
14. Samuel BS,Shaito A,Motoike T,Rey FE,Backhed F,Manchester JK,Hammer RE,Williams SC,Crowley J,Yanagisawa M,Gordon JI. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-Acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008 105 16767-16772 PMID: 18931303 DOI: 10.1073/pnas.0808567105]
15. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235-243 [PMID: 16633129]
16. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut 1994; 35: S35-S38 [PMID: 8125387]
17. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahash i D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450 [PMID: 2422677 0 DOI: 10.1038/nature12721]
18. Holzer P, Reichmann F, Farzi A. NEuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. NEuropeptides 2012; 46: 261-274 [PMID: 22979996 DOI: 10.1016/j.npep.2012.08.005]
19. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-259 [PMID: 16299351]
20. Groh H, Schade K, Hörhold-Schubert C. Steroid metabolism with intestinal microorganisms. J Basic Microbiol 1993; 33: 59-72 [PMID: 8478793]
21. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4523-4530 [PMID: 20 837534 DOI: 10.1073/pnas.1006734107]
22. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63 [PMID: 21475195 DOI: 10.1038/nature09922]
23. Martin FP, Sprenger N, Montoliu I, Rezzi S, Kochhar S, Nicholson JK. Dietary modulation of gut functional ecology studied by fecal metabonomics. J Proteome Res 2010; 9: 5284-5295 [PMID: 20806900 DOI: 10.1 021/pr100554m]
24. Lord RS, Bralley JA. Clinical applications of urinary organic acids. Part 2. Dysbiosis markers. Altern Med Rev 2008; 13: 292-306 [PMID: 19152477]
25. Zheng X, X ie G, Zhao A, Zhao L, Yao C, Chiu NH, Zhou Z, Bao Y, Jia W, Nicholson JK, Jia W. The footprints of gut microbialmammalian co-metabolism. J Proteome Res 2011; 10: 5512-5522 [PMID: 21970572 DOI: 10.1021/pr2007945]
26. Yokoyama MT, Carlson JR. Microbial metabolites of tryptophan in the intestinal tract with special reference to skatole. Am J Clin Nutr 1979; 32: 173-178 [PMID: 367144]
27. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM. The intestinal microbiota affect central levels of brain-deriv ed neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609, 609.e1-3 [PMID: 21683077 DOI: 10.1053/j.gastro.2011.04.052]
28. Keszthelyi D, Troost FJ, Masclee AA. Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function. Neurogastroenterol Motil 2009; 21: 1239-1249 [PMID: 19650771 DOI: 10.1111/j.1365-2982.2009.01370.x]
29. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley RE. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4578-4585 [PMID: 20668239 DOI: 10.1073/pnas.1000081107]
30. Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J 2011; 437: 357-372 [PMID: 21749321 DOI: 10.1042/BJ20110326]
31. Hanfrey CC, Pearson BM, Hazeldine S, Lee J, Gaskin DJ, Woster PM, Phillips MA, Michael AJ. Alternative spermidine biosynthetic route is critical for growth of Campylobacter jejuni and is the dominant polyamine pathway in human gut microbiota. J Biol Chem 2011; 286: 43301-43312 [PMID: 22025614 DOI: 10.1074/jbc. M111.307835]
32. Matsumoto M, Benno Y. The relationship between microbiota and polyamine concentration in the human intestine: a pilot study. Microbiol Immunol 2007; 51: 25-35 [PMID: 17237596]
33. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferriéres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endot oxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772 [PMID: 17456850]
34. Serino M, Luche E, Gres S, Baylac A, BergéM, Cenac C, Waget A, Klopp P, Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, OuarnéF, Monsan P, Valet P, Roques C, Amar J, BouloumiéA, Théodorou V, Burcelin R. Metabolic adaptation to a high-fat diet is associated with a change i n the gut microbiota. Gut 2012; 61: 543-553 [PMID: 22110050 DOI: 10.1136/gutjnl-2011-301012]
35. Cryan JF, Dinan TG. Mind-Altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-712 [PMID: 22968153 DOI: 10.1038/nrn3346]
36. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry 2013; 74: 720-726 [PMID: 23759244 DOI: 10.1016/j.biopsych.2013.05.001]
37. Lyte M. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori. Med Hypotheses 2010; 74: 895-897 [PMID: 19962247 DOI: 10.1016/j.mehy.2009.11.001]
38. Hyland NP, Cryan JF. A gut feeling about GABA: Focus on GABA(B) receptors. Front Pharmacol 2010; 1: 124 [PMID: 21833169 DOI: 10.3389/fphar.2010.00124]
39. O'Mahony SM, Clar ke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 2015; 277: 32-48 [PMID: 25078296 DOI: 10.1016/j.bbr.2014.07.027]
40. Dinan TG, Cryan JF. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 2012; 37: 1369-1378 [PMID: 22483040 DOI: 10.1016/j.psyneuen.2012.03.007]
41. Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev 2013; 14: 950-959 [PMID: 23947604 DOI : 10.1111/obr.12068]
42. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 2012; 57: 3126-3135 [PMID: 22684624 DOI: 10.1007/s10620-012-2259-4]
43. Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003; 52: 1442-1447 [PMID: 12970137]
44. Ohata A, Usami M, Miyoshi M. Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. Nutrition 2005; 21: 838-847 [PMID: 15975492]
45. Miyoshi M, Usami M, Ohata A. Short-chain fatty acids and trichostatin A alter tight junction permeability in human umbilical vein endothelial cells. Nutrition 2008; 24: 1189-1198 [PMID: 18723323 DOI: 10.1016/j.nut.2008.06.012]
46. Usami M, Miyoshi M, Kanbara Y, Aoyama M, Sakaki H, Shuno K, Hirata K, Takahashi M, Ueno K, Hamada Y, Tabata S, Asahara T, Nomoto K. Analysis of fecal microbiota, organic acids and plasma lipids in hepatic cancer patients with or without liver cirrhosis. Clin Nutr 2013; 32: 444-451 [PMID: 23068014 DOI: 10.1016/j.clnu.2012.09.010]
47. Ohira H, Fujioka Y, Katagiri C, Yano M, Mamoto R, Aoyama M, Usami M, Ikeda M. Butyrate enhancement of inteleukin-1? production via activation of o xidative stress pathways in lipopolysaccharide-stimulated THP-1 cells. J Clin Biochem Nutr 2012; 50: 59-66 [PMID: 22247602 DOI: 10.3164/jcbn.11-22]
48. Aoyama M, Kotani J, Usami M. Butyrate and p ropionate induced activated or non-Activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 2010; 26: 653-661 [PMID: 20004081 DOI: 10.1016/j.nut.2009.07.006]
49. Miyoshi M, Sakaki H, Usami M, Iizuka N, Shuno K, Aoyama M, Usami Y. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 2011; 30: 252-258 [PMID: 21051124 DOI: 10.1016/j.clnu.2010.09.012]
50. Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong CH. Sh ort chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin Nutr 2009; 28: 657-661 [PMID: 19523724 DOI: 10.1016/j.clnu.2009.05.011]
51. Bloemen JG, Olde Dam ink SW, Venema K, Buurman WA, Jalan R, Dejong CH. Short chain fatty acids exchange: Is the cirrhotic, dysfunctional liver still able to clear them? Clin Nutr 2010; 29: 365-369 [PMID: 19897285 DOI: 10.1016 /j.clnu.2009.10.002]
52. Miyauchi S, Hirasawa A, Ichimura A, Hara T, Tsujimoto G. New frontiers in gut nutrient sensor research: free fatty acid sensing in the gastrointestinal tract. J Pharmacol Sci 2010; 112: 19-24 [PMID: 20093784]
53. Dockray GJ. Gastrointestinal hormones and the dialogue between gut and brain. J Physiol 2014; 592: 2927-2941 [PMID: 24566540 DOI: 10.1113/jphysiol.2014.270850]
54. Steele RD. Blood-brain barrier transport of the alpha-keto acid analogs of amino acids. Fed Proc 1986; 45: 2060-2064 [PMID: 3519290]
55. Vijay N, M orris ME. Role of monocarboxylate transporters in drug delivery to the brain. Curr Pharm Des 2014; 20: 1487-1498 [PMID: 23789956]
56. Kekuda R, Manoharan P, Baseler W, Sundaram U. Monoca rboxylate 4 mediated butyrate transport in a rat intestinal epithelial cell line. Dig Dis Sci 2013; 58: 660-667 [PMID: 23344966 DOI: 10.1007/s10620-012-2407-x]
57. Maurer MH,Canis M,Kuschinsky W,Duelli R. Correlation between local monocarboxylate transporter 1 (MCT1) and glucose transporter 1 (GLUT1) densities in the adult rat brain Neurosci Lett 2004 355 105-108 PMID: 14729246]
58. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29: 625-651 [PMID: 16102595]
59. Vaquero J , Monte MJ, Dominguez M, Muntané J, Marin JJ. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem Pharmacol 2013; 86: 926-939 [PMID: 23928191 DOI: 10.1016/j.bcp.2013.07.022]
60. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]
61. Eisenhofer G, Aneman A, Friberg P, Hooper D, Få ndriks L, Lonroth H, Hunyady B, Mezey E. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997; 82: 3 864-3871 [PMID: 9360553]
62. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N. Critical role of gut microbiota in the production of biologically active, free catechola mines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol 2012; 303: G1288-G1295 [PMID: 23064760 DOI: 10.1152/ajpgi.00341.2012]
63. Orihata M, Sarna SK. Inhib ition of nitric oxide synthase delays gastric emptying of solid meals. J Pharmacol Exp Ther 1994; 271: 660-670 [PMID: 7525940]
64. Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. ?-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 2012; 113: 411-417 [PMID: 22612585 DOI: 10.1111/j.1365-2672.2012.05344.x]
65. Ventura M, Turro ni F, Zomer A, Foroni E, Giubellini V, Bottacini F, Canchaya C, Claesson MJ, He F, Mantzourani M, Mulas L, Ferrarini A, Gao B, Delledonne M, Henrissat B, Coutinho P, Oggioni M, Gupta RS, Z hang Z, Beighton D, Fitzgerald GF, O'Toole PW, van Sinderen D. The Bifidobacterium dentium Bd1 genome sequence reflects its genetic adaptation to the human oral cavity. PLoS Genet 2009; 5: e1000785 [PMID: 20041198 DOI: 1 0.1371/journal. pgen.1000785]
66. Lyte M. Microbial endocrinology and infectious disease in the 21st century. Trends Microbiol 2004; 12: 14-20 [PMID: 14700547]
67. Sadik R, Abrahamsson H, Björnsson E, Gunnarsdottir A, Stotzer PO. Etiology of portal hypertension may influence gastrointestinal transit. Scand J Gastroenterol 2003; 38: 1039-1044 [PMID: 14621277]
68. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209 [PMID: 23993913 DOI: 10.1016/j.jhep.2013.07.044]
69. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pand a k WM, Sikaroodi M, Gillevet PM. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014; 39: 1113-1125 [PMID: 24628464 DOI: 10.1111/apt.12695]
70. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004; 34: 9-19 [PMID: 15670660]
71. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
72. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Tolllike receptor 4 is involved in the mechanism of early alcoholinduced liver injury in mice. Hepatology 2001; 34: 101-108 [PMID: 11431739]
73. Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010; 2010: [PMID: 20706677 DOI: 10.1155/2010/192543]
74. Farrell GC, va n Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012; 6: 149-171 [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149]
75. Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012; 2012: 694629 [PMID: 22848224 DOI: 10.1155/2012/694629]
76. Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol 2008; 42 Suppl 2: S80-S84 [PMID: 18542037 DOI: 10.1097/MCG.0b013e318169c44e]
77. Rayes N, Seehofer D, Hansen S, Boucsein K, Müller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74: 123-127 [PMID: 12134110]
78. Rayes N,Seehofer D,Theruvath T,Schiller RA,Langrehr JM,Jonas S,Bengmark S,Neuhaus P. Supply of pre-And probiotics reduces bacterial infe ction rates after liver transplantation-A randomized, double-blind trial Am J Transplant 2005 5 125-130 PMID: 15636620]
79. Usami M, Miyoshi M, Kanbara Y, Aoyama M, Sakaki H, Shuno K, Hirata K, Takahashi M, Ueno K, Tabata S, Asahara T, Nomoto K. Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or withou t cirrhosis. JPEN J Parenter Enteral Nutr 2011; 35: 317-328 [PMID: 21527594 DOI: 10.1177/01 48607110379813]
80. Pitsouni E, Alexiou V, Saridakis V, Peppas G, Falagas ME. Does th e use of probiotics/synbiotics prevent postoperative infections in patients undergoing abdominal surgery A meta-Analysis of randomized controlled trials. Eur J Clin Pharmacol 2009; 65: 561-570 [PMID: 19326107 DOI: 10.1007/s00228-009-0642-7]
81. Jayakumar S, Carbonneau M, Hotte N, Befus AD, St Laurent C, Owen R, McCarthy M, Madsen K, Bailey RJ, Ma M, Bain V, Rioux K, Tandon P. VSL#3® probiotic the rapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int 2013; 33: 1470-1477 [PMID: 23968203 DOI: 10.1111/liv.12280]
82. Rincón D, Vaquero J, Hernando A, Galindo E, Ripoll C, Puerto M, Salcedo M, Francés R, Matilla A, Catalina MV, Clemente G, Such J, Bañares R. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int 2014; 34: 1504-1512 [PMID: 24661740 DOI: 10.1111/liv.12539]
83. Pawar RR, Pardeshi ML, Ghongane BB. Study of effects of probiotic lactobacilli in preventing major complications in patients of liver cirrhosis. Value Health 2012; 3: 206-211
84. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlle d trial. Clin Gastroenterol Hepatol 2014; 12: 1003-8.e1 [PMID: 24246768 DOI: 10.1016/j.cgh.2013.11.006]
85. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443]
86. Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol 2015; 7: 559-565 [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559]
87. Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova F, Uribe M. Intestinal flora, probiotics, and cirrhosis. Ann Hepatol 2008; 7: 120-124 [PMID: 18626428]
88. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a d oubleblind placebo-controlled study. Nutrition 2011; 27: 177-181 [PMID: 20452184 DOI: 10.1016/j.nut.2010.01.006]
89. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis 2004; 5: 64-67 [PMID: 15612659]
90. Liu JE, Zhang Y, Zhang J, Dong PL, Chen M, Duan ZP. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease. Nurs Res 2010; 59: 426-432 [PMID: 21048484 DOI: 10.1097/NNR.0b013e3181fa4dc6]
91. Lata J, Novotný I, PríbramskáV, Juránková J, Fric P, Kroupa R, Stibrek O. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111-1113 [PMID: 17998837]
92. Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int 2013; 3 3: 1148-1157 [PMID: 23601333 DOI: 10.1111/liv.12172]
93. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probio tic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-1715 [PMID: 18691193 DOI: 10.1111/j.1572-0241.2008.01861.x]
94. Eguchi S, Takatsuki M, Hid aka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg 2011; 2 01: 498-502 [PMID: 20619394 DOI: 10.1016/j.amjsurg.2010.02.013]
95. Bengmark S. Ecoimmunonutrition: a challenge for the third millennium. Nutrition 1998; 14: 563-572 [PMID: 9684258]
96. Delzenne NM, Williams CM. Prebiotics and lipid metabolism. Curr Opin Lipidol 2002; 13: 61-67 [PMID: 11790964]
97. Karagozian R, Derdák Z, Baffy G. Obesity-Associated mechanisms of hepatocarcinogenesis. Metabolism 2014; 63: 607-617 [PMID: 24629562 DOI: 10.1016/j.metabol.2014.01.011]
98. Wall R, Ross RP, Shanahan F, O'Mahony L, Kiely B, Quigley E, Dinan TG, Fitzgerald G, Stanton C. Impact of administered bifidobacterium on murine host fatty acid composition. Lipi ds 2010; 45: 429-436 [PMID: 20405232 DOI: 10.1007/s11745-010-3410-7]
99. Wall R, Ross RP, Shanahan F, O'Mahony L, O'Mahony C, Coakley M, Hart O, Lawlor P, Quigley EM, Kiely B, Fitzgerald GF, Stanton C. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 2009; 89: 1393-1401 [PMID: 19357220 DOI: 10.3945/ajcn.2008.27023]
100. Nagao K, Inoue N, Wang YM, Shirouchi B, Yanagita T. Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Nutr 2005; 135: 9-13 [PMID: 15623825]
101. KankaanpääPE, Yang B, Kallio HP, Isolauri E, Salminen SJ. Influence of probiotic supplemented infant formula on composition of plasma lipids in atopic infants. J Nutr Biochem 2002; 13: 364-369 [PMID: 12088802]
102. Miyoshi H , Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T, Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K. Pathogenesis of lipid metabolism disorder in hepati tis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol 2011; 54: 432-438 [PMID: 21093950 DOI: 10.1016/j.jhep.2010.07.039]
103. Bugianesi E, Salamo ne F, Negro F. The interaction of metabolic factors with HCV infection: does it matter J Hepatol 2012; 56 Suppl 1: S56-S65 [PMID: 22300466 DOI: 10.1016/S0168-8278(12)60007-5]
104. Irmisch G, Hoeppner J, Thome J, Richter J, Fernow A, Reisinger EC, Lafrenz M, Loebermann M. Serum fatty acids, antioxidants, and treatment response in hepatitis C infection: greater polyunsaturated fatty acid and antioxidant level s in hepatitis C responders. J Clin Lipidol 2011; 5: 288-293 [PMID: 21784374 DOI: 10.1016/j.jacl.2011.04.005]
105. Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, Haid S, Gentzsch J, Kaderali L, Bartenschlager R, Pietschmann T. MAPkinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog 2012; 8: e1002829 [PMID: 2291 1431 DOI: 10.1371/journal. ppat.1002829]
106. Popescu CI, Riva L, Vlaicu O, Farhat R, RouilléY, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) 2014; 3: 892-921 [PMID: 25517881 DOI: 10.3390/biology3040892]
107. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishika wa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101 [PMID: 23803760 DOI: 10.1038/nature12347]
108. Fiehn O, Barupal DK, Kind T. Extending biochemical databases by metabolomic surveys. J Biol Chem 2011; 286: 23637-23643 [PMID: 21566124 DOI: 10.1074/jbc.R110.173617]